Sign up
Pharma Capital

Zelda Therapeutics expands medical cannabis clinical trial

The company will expand its clinical research to include autism.
Zelda shares are up 220% in 2017, priced at $0.125

Zelda Therapeutics (ASX:ZLD) has expanded its medical cannabis clinical trial program in Chile to include autism, which is expected to commence in the second half of 2017.

Autism is a lifelong development disability characterized by impairments in social communication and interactions.

The global market for autism diagnosis and treatments is expected to grow to US$412.7 million by 2019.

Zelda will work together with Chilean non-profit patient advocate group Fundación Daya, leveraging their clinical experiences with autism patients.

Harry Karelis, executive chairman, commented: “Our investment into conducting a rigorous and controlled clinical trial paves the way for product registrations next year significantly improving patient access to a novel form of treatment.

“Our intention would be to replicate this trial in other key jurisdictions to rapidly improve patient access in other jurisdictions.”

Chile’s advantage

The legal framework in Chile recognises the importance of medical cannabis, allowing its production under strict regulatory controls for the treatment of medical conditions.

The country also provides a cost-effective location for Zelda to conduct clinical trials.

Furthermore, Zelda through its relationship with AusCann Group Holdings (ASX:AC8) will leverage Auscann’s Chilean joint-venture DayaCann to supply high quality medical cannabis for the autism trial.

Fundación Daya has extensive experience over a number of years in using medical cannabis to treat patients diagnosed with autism.

This clinical experience demonstrates solid anecdotal evidence of positive quality of life outcomes using cannabinoid-based therapy.

Trial details

Subject to regulatory approvals being obtained, Zelda expects the trial will commence in the second half of 2017, with trial protocols already being developed.

Zelda expects the trial to be conducted over a period of 3-6 months.

Well-funded pathway to revenue

Zelda’s recent $6.0 million capital raising provides it with increased flexibility to pursue new opportunities and diversify such as this.

Successful results will allow Zelda to immediately commence the product registration process to sell clinically approved products in the Chilean market.

This provides a clear pathway to potential revenue generation from Chile and other South American markets as early as 2018.

Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.